Form 8-K - Current report:
SEC Accession No. 0000950170-25-054484
Filing Date
2025-04-16
Accepted
2025-04-16 08:00:09
Documents
13
Period of Report
2025-04-16
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K aktx-20250416.htm   iXBRL 8-K 51406
2 EX-99.1 aktx-ex99_1.htm EX-99.1 238378
3 GRAPHIC img218604663_0.jpg GRAPHIC 67599
  Complete submission text file 0000950170-25-054484.txt   619934

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT aktx-20250416.xsd EX-101.SCH 97669
15 EXTRACTED XBRL INSTANCE DOCUMENT aktx-20250416_htm.xml XML 6056
Mailing Address 22 BOSTON WHARF ROAD FL 7 BOSTON MA 02210
Business Address 22 BOSTON WHARF ROAD FL 7 BOSTON MA 02210 (646) 350-0702
Akari Therapeutics Plc (Filer) CIK: 0001541157 (see all company filings)

EIN.: 981034922 | State of Incorp.: X0
Type: 8-K | Act: 34 | File No.: 001-36288 | Film No.: 25841252
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)